Healthcare
Sensorium – SUCCESS PAGE – March 3, 2025
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Sigyn Therapeutics [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, infectious diseases, and more
Alzheon is a clinical-stage biopharma company with a first-in-class oral treatment targeting the root cause of Alzheimer’s disease.
Alzheon is a clinical-stage biopharma company with a first-in-class oral treatment targeting the root cause of Alzheimer’s disease.
The only publicly traded business accelerator and holding company in the U.S. for Nordic life science companies.
A clinical-stage precision medicine company enhancing patient outcomes through improved decision-making and personalized cancer care.
The only publicly traded business accelerator and holding company in the U.S. for Nordic life science companies.
A clinical-stage precision medicine company enhancing patient outcomes through improved decision-making and personalized cancer care.
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease
OncoOne has created a diverse pipeline of treatment options for solid tumor cancers as well as inflammatory diseases including rheumatoid arthritis
1460 Broadway
New York, NY 10036
(917) 747-6198
© Copyright 2025 FORCE Family Office
